Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
O'Malley DM, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, Swisher EM, Maloney L, Goble S, Lin KK, Kwan T, Ledermann JA, Coleman RL.
O'Malley DM, et al. Among authors: goh jc.
Gynecol Oncol. 2022 Dec;167(3):404-413. doi: 10.1016/j.ygyno.2022.08.021. Epub 2022 Oct 20.
Gynecol Oncol. 2022.
PMID: 36273926
Free PMC article.
Clinical Trial.
Molecular features (genomic alterations, BRCA1 promoter methylation) and baseline clinical characteristics were evaluated for association with exceptional benefit (progression-free survival 2 years) versus progression on first scan (short-term subgroup) and other efficacy …
Molecular features (genomic alterations, BRCA1 promoter methylation) and baseline clinical characteristics were evaluated for association wi …